Hepatocellular carcinoma is a difficult-to-treat cancer and, after numerous phase III trials assessing kinase inhibitors have failed to meet their end points, sorafenib is the only accepted treatment for advanced stages of the disease. Now, the trial EVOLVE-1 has shown a lack of benefit for everolimus in the second-line treatment setting.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
GBAP1 functions as a tumor promotor in hepatocellular carcinoma via the PI3K/AKT pathway
BMC Cancer Open Access 05 July 2023
-
Septin11 promotes hepatocellular carcinoma cell motility by activating RhoA to regulate cytoskeleton and cell adhesion
Cell Death & Disease Open Access 20 April 2023
-
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit
Scientific Reports Open Access 12 August 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
European Association for the Study of the Liver and European Association for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).
Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245–1255 (2012).
Llovet, J. M. & Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37, 429–442 (2003).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
Llovet, J. M. & Hernández-Gea, V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin. Cancer Res. 20, 2072–2079 (2014).
Villanueva, A. et al. Pivotal role of mTOR signaling in HCC. Gastroenterology 135, 1972–1983 (2008).
Zhu, A. et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib. JAMA 312, 57–67 (2014).
Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).
Farazi, P A. & DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674–687 (2006).
Villanueva, A. & Llovet, J. M. Liver cancer in 2013: Mutational landscape of HCC-end of the beginning. Nat. Rev. Clin. Oncol. 11, 73–74 (2014).
Acknowledgements
J.M.L. is supported by grants from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK076986-01), European Commission-FP7 Framework (HEPTROMIC, Proposal No: 259,744), the Asociación Española Contra el Cáncer, the Samuel Waxman Cancer Research Foundation and the Spanish National Health Institute (SAF-2010-16055).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.M.L. is a consultant for Bayer Pharmaceuticals, Blueprint, Boeringher-Ingelheim, Bristol–Myers Squibb, Celsion, Imclone-Lilly, Novartis, and provides research support for Bayer Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Llovet, J. Time to evolve trial design after everolimus failure. Nat Rev Clin Oncol 11, 506–507 (2014). https://doi.org/10.1038/nrclinonc.2014.136
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.136
This article is cited by
-
GBAP1 functions as a tumor promotor in hepatocellular carcinoma via the PI3K/AKT pathway
BMC Cancer (2023)
-
Septin11 promotes hepatocellular carcinoma cell motility by activating RhoA to regulate cytoskeleton and cell adhesion
Cell Death & Disease (2023)
-
Targeting mTOR by CZ415 Suppresses Cell Proliferation and Promotes Apoptosis via Lipin-1 in Cervical Cancer In Vitro and In Vivo
Reproductive Sciences (2021)
-
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit
Scientific Reports (2019)
-
NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression
Oncogene (2018)